Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease.
J Immunol
; 160(10): 5188-94, 1998 May 15.
Article
em En
| MEDLINE
| ID: mdl-9590272
ABSTRACT
An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), is a major target of T cells in brain lesions of multiple sclerosis (MS), and this peptide can trigger experimental autoimmune encephalomyelitis (EAE). We designed truncated peptides based on this pathogenic 13-mer that are not antigenic. These short peptides reduced production of IFN-gamma and TNF-alpha in vivo. Moreover, paraplegic rats given the 7-mer FKNIVTP in soluble form showed total reversal of paralysis in 24 h. Truncated peptides that are too small to stimulate antigenic responses to pathogenic regions of myelin basic protein are nevertheless effective tolerogens and are able to anergize autoreactive T cells. Short peptide-based tolerogens, devoid of immunogenic and pathogenic potential, may be attractive for therapy of autoimmune diseases.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fragmentos de Peptídeos
/
Proteína Básica da Mielina
/
Encefalomielite Autoimune Experimental
/
Tolerância Imunológica
Tipo de estudo:
Etiology_studies
Limite:
Animals
Idioma:
En
Revista:
J Immunol
Ano de publicação:
1998
Tipo de documento:
Article